Project Grant P01HL172729
Award Date
9/17/24
Completion Date
7/31/29
Dollars Obligated
$5.7M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Nashville, TN 37203, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), provides $651,019 to the Regents of the University of Michigan to conduct research on dysfunctional epithelial repair in pulmonary fibrosis. The key focus of this 4-year project is to elucidate the factors and pathways that contribute to aberrant epithelial cell states in persistent lung fibrosis, with the goal of identifying...
This $774,585 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research to investigate the mechanisms underlying the emergence and functional role of inflammatory fibroblasts in pulmonary fibrosis. Key research activities include: Comparing the timing, persistence, and fate of inflammatory fibroblasts in mouse models of pulmonary fibrosis (bleomycin, silica) versus an...
This $1,546,880 five-year federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the regulation of myofibroblast gene expression in idiopathic pulmonary fibrosis (IPF). The research aims to determine the "regulatory architecture" of open chromatin regions in IPF myofibroblasts, examine how expression of E-box transcription factors like TWIST1 regulate...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), is funded under the Cardiovascular Diseases Research program (CFDA 93.837). The $542,402 grant, awarded on April 1, 2025, supports a collaborative research project between Henry Ford Health and Michigan State University Health Sciences to identify small molecule compounds that can reverse profibrotic gene signatures in idiopathic pulmonary fibrosis...
This $277,610 Project Grant awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to determine the role of TP53 regulation in alveolar epithelial transitional cell state, and the contribution of alveolar epithelial transitional cell state to pulmonary fibrosis. The research aims to uncover the molecular mechanisms that regulate alveolar epithelial cell states and their impact on pulmonary fibrosis, a debilitating and terminal...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $683,564 to The Trustees of the University of Pennsylvania to study the role of alveolar epithelial cell stress signaling in the development of pulmonary fibrosis. The project aims to determine how aberrant transitional alveolar epithelial cells contribute to fibrosis and to define the impact of the PERK-integrated stress response pathway on epithelial...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,061,189 to support research on immune crosstalk in lung injury and fibrosis. The key objectives are: 1) studying epithelial HB-EGF regulation of fibrosis and its interaction with myeloid cells, 2) uncovering mechanisms for impaired innate immunity against gram-positive infections...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $134,123.00 to The Regents of the University of California, San Francisco (UCSF) to investigate pulmonary fibrosis biology in pediatric hematopoietic cell transplant patients. The key objectives are to: 1) Identify bronchoalveolar lavage fluid and blood biomarker signatures that distinguish pediatric hematopoietic cell transplant...
This federal Project Grant award in the amount of $797,845 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to Vanderbilt University Medical Center. The award supports research to better understand the progression of pulmonary fibrosis, a fatal lung disease, across the full disease development history. The project aims to fit and validate a Bayesian disease progression model to define the conserved,...
This $827,753.00 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of computational methods for systems genetic analysis of the rare, polygenic disorder Idiopathic Pulmonary Fibrosis (IPF). The project aims to: Develop a new network model-based association test informed by pleiotropy to gene expression traits, which will be applied to IPF GWAS and eQTL data. Create a...